PRODUCT

CJC-1295 NO DAC + Ipamorelin (10 mg Blend)

No short description available.

Quickstart Highlights

This blend combines CJC-1295 (no DAC), a modified growth hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue (GHS)[1][2]. CJC-1295 (no DAC) produces sustained, dose-dependent GH and IGF-1 increases[1], while Ipamorelin selectively stimulates GH release without raising ACTH or cortisol[3]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL total concentration (1.67 mg/mL each peptide).
Typical daily range: 100–300 mcg of each peptide once daily (gradual titration).
Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 33.3 mcg of each peptide on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Reconstitution

Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light.
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Protocol Overview

Goal:Support pulsatile GH release through synergistic GHRH + GHS stimulation[4].
Schedule:Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Dose Range:100–300 mcg of each peptide daily with gradual titration.
Reconstitution:3.0 mL per 10 mg vial (~3.33 mg/mL total) for accurate unit measurements.
Storage:Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosage Protocols

Start:100 mcg each peptide daily; increase by ~50 mcg every 1–2 weeks as tolerated.
Target:200–300 mcg each peptide daily by Weeks 5–12.
Frequency:Once per day (subcutaneous).
Cycle Length:8–12 weeks; optional extension to 16 weeks.
Timing:Typically before bed or upon waking; rotate injection sites.

Storage Instructions

Lyophilized:Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted:Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~28 days; avoid freeze–thaw.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily dose and site rotation to maintain consistency.
For doses under 10 units, use 30- or 50-unit syringes for better precision.

How It Works

CJC-1295 (no DAC) is a modified GHRH analog (tetrasubstituted 29-amino acid peptide) that stimulates pulsatile GH release from the pituitary[1]. Human studies demonstrate sustained, dose-dependent increases in both GH and IGF-1 with subcutaneous administration[1]. Ipamorelin is a pentapeptide GH secretagogue with a half-life of approximately 1.5–2.5 hours[5] that elicits a rapid GH pulse peaking around 40 minutes post-dose[6]. Importantly, Ipamorelin selectively increases GH without affecting ACTH, cortisol, or prolactin levels[3]. When combined, these peptides may produce synergistic GH release by acting on complementary receptor pathways[4].

Lifestyle Factors

Pair with a balanced, protein-forward diet tailored to energy needs.
Combine resistance training and aerobic activity to reinforce metabolic adaptations.
Prioritize sleep quality, as GH is predominantly released during deep sleep.
Manage stress to support optimal hormonal balance and recovery.

Injection Technique

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[7][8].
Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[9].

Benefits and Side Effects

Benefits

Supports sustained GH and IGF-1 elevation through pulsatile release patterns[1][2].
Ipamorelin demonstrates selective GH release without cortisol or ACTH elevation[3].
Once-daily dosing of CJC-1295 (no DAC) has been shown to normalize growth in animal models[2].
Some individuals report increased appetite, water retention, or tingling sensations.

Side Effects

Generally well tolerated; possible transient effects may include flushing, headache, or injection-site reactions.

CJC-1295 NO DAC + Ipamorelin (10 mg Blend)

Resources

Categories

Company